CFO
GLSI icon

CVA Family Office’s Greenwich LifeSciences GLSI Stock Holding History

CVA Family Office’s Portfolio GLSI Stock Details GLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$235 Hold
10
– – ﹤0.01% 1766
2026
Q1 		$240 Buy
+10
New +$261 ﹤0.01% 1804

Other funds holding GLSI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CVA Family Office's GLSI Position: Q2 2026 in Review

CVA Family Office held its Greenwich LifeSciences (GLSI) position steady in Q2 2026 at 10 shares worth $235. The position accounts for ﹤0.01% of the portfolio, ranked #1766.

CVA Family Office first reported a position in GLSI in Q1 2026 and has held it in 2 quarters since. The position peaked at $240 in Q1 2026. 58 funds tracked by Wall St. Rank hold GLSI as of Q2 2026.

  • CVA Family Office held 10 shares of Greenwich LifeSciences worth $235 as of Q2 2026.
  • CVA Family Office left its Greenwich LifeSciences share count unchanged in Q2 2026.
  • Greenwich LifeSciences made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1766 holding.
  • CVA Family Office first reported a position in Greenwich LifeSciences in Q1 2026 and has held it in 2 quarters since.
  • CVA Family Office's Greenwich LifeSciences position peaked at $240 in Q1 2026.
  • 58 funds tracked by Wall St. Rank held Greenwich LifeSciences as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.